Feasibility of the administration of chemotherapy using cisplatin plus etoposide for non-small cell lung cancer patients with interstitial lung disease on chest computed tomography

Johnston, 1997, British thoracic society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing alveolitis subcommittee of the research committee of the british thoracic society, Thorax, 52, 38, 10.1136/thx.52.1.38 Turner-Warwick, 1980, Cryptogenic fibrosing alveolitis and lung cancer, Thorax, 35, 496, 10.1136/thx.35.7.496 Wells, 1994, Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis, Am. J. Respir. Crit. Care Med., 149, 1583, 10.1164/ajrccm.149.6.8004317 Hubbard, 2000, Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study, Am. J. Respir. Crit. Care Med., 161, 5, 10.1164/ajrccm.161.1.9906062 Harris, 2010, Cryptogenic fibrosing alveolitis and lung cancer: the BTS study, Thorax, 65, 70, 10.1136/thx.2009.121962 Demedts, 2005, High-dose acetylcysteine in idiopathic pulmonary fibrosis, N. Engl. J. Med., 353, 2229, 10.1056/NEJMoa042976 Taniguchi, 2010, Pirfenidone in idiopathic pulmonary fibrosis, Eur. Respir. J., 35, 821, 10.1183/09031936.00005209 Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer, Cochrane Database Syst. Rev., 2010, CD007309. Shepherd, 2000, Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, J. Clin. Oncol., 18, 2095, 10.1200/JCO.2000.18.10.2095 Raghu, 2011, An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management, Am. J. Respir. Crit. Care Med., 183, 788, 10.1164/rccm.2009-040GL Goldstraw, 2007, The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours, J. Thorac. Oncol., 2, 706, 10.1097/JTO.0b013e31812f3c1a W.D. Travis, B. Corrin, Y. Shimosato, et al., Histological typing of lung and pleural tumors, World Health Organization International Histological Classification of Tumors, Springer Verlag Berlin, 1999 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur. J. Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 U.S. Department of Health and Human Services NIoH, National Cancer Institute, National Cancer Institute Common Terminology Criteria for Adverse Event version 4.0.CTCAE Noda, 2002, Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer, N. Engl. J. Med., 346, 85, 10.1056/NEJMoa003034 Olson, 2007, Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003, Am. J. Respir. Crit. Care Med., 176, 277, 10.1164/rccm.200701-044OC Network NCC, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Non-Small Cell Lung Cancer version 2, 2013, 〈www.nccn.com〉. Reck, 2014, Metastatic non-small-cell lung cancer (NSCLC): esmo clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 25 Socinski, 2013, Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: american College of Chest Physicians evidence-based clinical practice guidelines, Chest, 143, e341S, 10.1378/chest.12-2361 Minegishi, 2009, Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy, Intern. Med., 48, 665, 10.2169/internalmedicine.48.1650 Shukuya, 2010, Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease, Anticancer Res., 30, 4357 Minegishi, 2011, The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias, Lung Cancer, 71, 70, 10.1016/j.lungcan.2010.04.014 Minegishi, 2011, The feasibility study of carboplatin plus etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias, J. Thorac. Oncol., 6, 801, 10.1097/JTO.0b013e3182103d3c Kenmotsu, 2011, The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer, J. Thorac. Oncol., 6, 1242, 10.1097/JTO.0b013e318216ee6b Yoshida, 2013, Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease, Anticancer Res., 33, 1175 Hanna, 2006, Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer, J. Clin. Oncol., 24, 2038, 10.1200/JCO.2005.04.8595 Klastersky, 1990, A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: european organization for research and treatment of cancer protocol 07861, J. Clin. Oncol., 8, 1556, 10.1200/JCO.1990.8.9.1556 Bonomi, 2000, Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an eastern cooperative oncology group trial, J. Clin. Oncol., 18, 623, 10.1200/JCO.2000.18.3.623 Belani, 2005, Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer, Ann. Oncol., 16, 1069, 10.1093/annonc/mdi216 Richeldi, 2014, Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis, N. Engl. J. Med., 370, 2071, 10.1056/NEJMoa1402584 Richeldi, 2011, Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis, N. Engl. J. Med., 365, 1079, 10.1056/NEJMoa1103690